Literature DB >> 6743351

Stimulation of K+ fluxes by diuretic drugs in human red cells.

R P Garay, C Nazaret, J Diez, A Etienne, R Bourgain, P Braquet, A Esanu.   

Abstract

Two different families of diuretic drugs--(i) (aryloxy)acetic acid diuretics (ethacrynic acid, tienilic acid and (--)-indacrinone) and (ii) furopyridines [(+/-)-BN 50157 and (+/-)-cycletanide]--stimulate K+ movements across human red cell membranes. The kinetic properties of this effect (K+-specificity, saturability, optical isomerism, antagonism by structural analogues, etc.) strongly suggest that it is mediated by a K+-transport system with a specific binding site for some diuretic drugs. The stimulated K+ fluxes are resistant to ouabain, bumetanide and quinine, thus suggesting that they are not mediated by the Na+,K+-pump, Na+,K+-cotransport or by the Ca2+-dependent K+-permeability ('Gardos effect'). The replacement of Cl- by NO3- ions can either decrease, increase or have no effect on the stimulated K+ fluxes, depending on the diuretic drug. Although not conclusive, these observations suggest that the K+ fluxes are not mediated by stimulation of a chloride-dependent K+ carrier. The study of structural analogues showed that the intensity of the stimulation of K+ fluxes is strongly correlated with the magnitude of the natriuretic effect. Curiously, some antiallergic furopyridines are able to inhibit K+ fluxes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743351     DOI: 10.1016/0006-2952(84)90567-7

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  The significance of the relative effects of loop diuretics and anti-brain edema agents on the Na+,K+,Cl- cotransport system and the Cl-/NaCO3- anion exchanger.

Authors:  R P Garay; P A Hannaert; C Nazaret; E J Cragoe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-10       Impact factor: 3.000

2.  Humoral and cellular effects of the K(+)-channel activator cromakalim in man.

Authors:  P Lijnen; R Fagard; J Staessen; T Weiping; E Moerman; A Amery
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Abnormal erythrocyte sodium leak in a subset of essential hypertensive patients.

Authors:  A De la Sierra; A Coca; M T Aguilera; A Urbano Márquez
Journal:  Klin Wochenschr       Date:  1989-01-04

4.  Demonstration of a Na+: Mg2+ exchange in human red cells by its sensitivity to tricyclic antidepressant drugs.

Authors:  J C Féray; R Garay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

5.  Influence of renal insufficiency on the pharmacokinetics of cicletanine and its effects on the urinary excretion of electrolytes and prostanoids.

Authors:  N Ferry; J Geoffroy; N Pozet; G Cuisinaud; D Benzoni; P Y Zech; J Sassard
Journal:  Br J Clin Pharmacol       Date:  1988-03       Impact factor: 4.335

Review 6.  Diuretics and cation transport in hypertensive blacks.

Authors:  A P Quintanilla; O E Wagener
Journal:  Cardiovasc Drugs Ther       Date:  1990-03       Impact factor: 3.727

7.  Activators of potassium channels enhance calcium influx into endothelial cells as a consequence of potassium currents.

Authors:  A Lückhoff; R Busse
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-07       Impact factor: 3.000

8.  Cicletanine sulfate: inhibition of anion transport systems and natriuretic activity.

Authors:  R P Garay; C Rosati; C Nazaret; A Esanu; T Tarrade; P Braquet
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-07       Impact factor: 3.000

9.  Effects of cicletanine on haemodynamics, arrhythmias and extent of necrosis during coronary ligation in rabbits.

Authors:  T Burton; S Chakrabarty; D S Fluck; N A Flores; D J Sheridan
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

10.  The interaction of canrenone with the Na+,K+ pump in human red blood cells.

Authors:  R P Garay; J Diez; C Nazaret; G Dagher; J P Abitbol
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.